New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2022, WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment.
View latest version (2022)Bibliographic information
GuidelineGuidelines for treatment of drug-susceptible tuberculosis and patient care
Year of Publication2017
Issuing InstitutionWorld Health Organization
Recommendation
Retired
In patients with drug-susceptible pulmonary TB, 4-month fluoroquinolone-containing regimens13 should not be used and the 6-month rifampicinbased regimen 2HRZE/4HR remains the recommended regimen
Recommended against
Strong
Certainty of evidence
Moderate